HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL

Creative Commons License

Carson R., ÇELTİKÇİ B., Fenning C., Javadi A., Crawford N., Perez-Carbonell L., ...More

CLINICAL CANCER RESEARCH, vol.21, no.14, pp.3230-3240, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 14
  • Publication Date: 2015
  • Doi Number: 10.1158/1078-0432.ccr-14-2701
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.3230-3240
  • Hacettepe University Affiliated: No


Purpose: Activating mutations in the BRAF oncogene are found in 8% to 15% of colorectal cancer patients and have been associated with poor survival. In contrast with BRAF-mutant (MT) melanoma, inhibition of the MAPK pathway is ineffective in the majority of BRAFMT colorectal cancer patients. Therefore, identification of novel therapies for BRAFMT colorectal cancer is urgently needed.